Hyundai Pharm (004310) — Cash Flow-to-Debt Ratio
Hyundai Pharm (004310) has a Cash Flow-to-Debt Ratio of 0.02x as of May 2026, meaning its operating cash flow of ₩2.39 Billion could theoretically repay 0% of its total liabilities (₩96.64 Billion) in one year. See 004310 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hyundai Pharm Cash Flow-to-Debt Ratio (2010–2025)
Historical debt coverage capacity for Hyundai Pharm across 14 annual periods. For the full cash flow conversion analysis, see 004310 cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Hyundai Pharm (2010–2025)
Year-by-year debt coverage analysis for Hyundai Pharm. Check 004310 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | ₩-123.29 Million | ₩81.11 Billion | ▲ +95.0% |
| 2024 | -0.03x | ₩-2.37 Billion | ₩77.32 Billion | ▲ +52.8% |
| 2023 | -0.06x | ₩-4.55 Billion | ₩69.97 Billion | ▼ -152.9% |
| 2022 | 0.12x | ₩11.62 Billion | ₩94.60 Billion | ▲ +85.0% |
| 2021 | 0.07x | ₩5.13 Billion | ₩77.26 Billion | ▼ -58.6% |
| 2020 | 0.16x | ₩10.80 Billion | ₩67.36 Billion | ▲ +33.4% |
| 2019 | 0.12x | ₩6.96 Billion | ₩57.89 Billion | ▲ +119.8% |
| 2018 | 0.05x | ₩2.83 Billion | ₩51.80 Billion | ▲ +256.1% |
| 2017 | -0.04x | ₩-1.98 Billion | ₩56.52 Billion | ▲ +35.6% |
| 2016 | -0.05x | ₩-2.75 Billion | ₩50.47 Billion | ▼ -128.9% |
| 2013 | 0.19x | ₩7.95 Billion | ₩42.19 Billion | ▲ +450.9% |
| 2012 | -0.05x | ₩-2.70 Billion | ₩50.22 Billion | ▼ -145.1% |
| 2011 | 0.12x | ₩6.27 Billion | ₩52.63 Billion | ▲ +71.1% |
| 2010 | 0.07x | ₩2.68 Billion | ₩38.48 Billion | — |